تحديد مستويات ميتالوبروتيناز المصفوفة 10 والفيتوين – أ لدى مرضى السكري العراقيين المصابين بإعتلال الكلية كعوامل تنبوء ممتازة

1. Amelia R, Sari DK, Muzasti RA, Fujiati II, Wijaya H. Early detection of diabetic nephropathy based on albumin creatinine ratio (ACR) in type 2 diabetes mellitus patients in Medan, Indonesia. Family Medicine Primary Care Review. 2021;23(2). https://doi.org/10.5114/fmpcr.2021.105903.

2. Ibrahim RK, Ghudhaib KK, Allawi AAD. Early prediction of nephropathy in Iraqi patient with diabetes type II by evaluating some relevant biochemical factors. Baghdad Science Journal 2024;21(5):1549-. https://doi.org/10.21123/bsj.2023.8008.

3. Salmana ZA, Ghudhaiba KK, Fadhilb R. Evaluating Osteocalcin and Osteonectin in serum male patients with type 2 Diabetes mellitus and periodontitis. Eurasian Chemical Communications. 2022;4(2022):295-302. https://doi.org/10.22034/ecc.2022.325049.1307.

4. Mohammed SK, Taha EM, Muhi SA. A case-control study to determination FBXW7 and Fetuin-A levels in patients with type 2 diabetes in Iraq. Journal of Diabetes & Metabolic Disorders. 2021;20(1):237-43. https://doi.org/10.1007/s40200-021-00738-x.

5. Jaid HK, Khaleel FM, Salman IN, Abd BA. Estimation of Apelin Levels in Iraqi Patients with Type II Diabetic Peripheral Neuropathy. Baghdad Science Journal 2023;20(5):1684-91. https://doi.org/10.21123/bsj.2023.7566

6. Farhan LO, Abed BA, Dawood A. Comparison Study between Adipsin Levels in Sera of Iraqi Patients with Diabetes and Neuropathy. Baghdad Science Journal. 2023;20(3):726-33. https://doi.org/10.21123/bsj.2022.7408.

7. Kyrou I, Tsigos C, Mavrogianni C, Cardon G, Van Stappen V, Latomme J, et al. Sociodemographic and lifestyle-related risk factors for identifying vulnerable groups for type 2 diabetes: a narrative review with emphasis on data from Europe. BMC Endocrine Disorders. 2020;20(1):134. https://doi.org/10.1186/s12902-019-0463-3.

8. Meenakshi S, Bahekar T, Narapaka PK, Pal B, Prakash V, Dhingra S, et al. Impact of fluorosis on molecular predictors in pathogenesis of type 2 diabetes associated microvascular complications. Journal of Trace Elements in Medicine and Biology. 2024;86:127506. https://doi.org/10.1016/j.jtemb.2024.127506.

9. Taub PR, Greene SJ, Fudim M. The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment. Heart Failure Reviews. 2025. https://doi.org/10.1007/s10741-025-10520-3.

10. Shan J, Ziyi C, and Yu S. Advances in Understanding Diabetic Kidney Disease Progression and the Mechanisms of Acupuncture Intervention. International Journal of General Medicine. 2024;17(null):5593-609. https://doi.org/10.2147/IJGM.S490049.

11. Folestad E, Mehlem A, Ning FC, Oosterveld T, Palombo I, Singh J, et al. Vascular endothelial growth factor B-mediated fatty acid flux in the adipose-kidney axis contributes to lipotoxicity in diabetic kidney disease. Kidney International. 2025;107(3):492-507. https://doi.org/10.1016/j.kint.2024.11.026.

12. Mohamed ON, Mohamed MRM, Hassan IG, Alakkad AF, Othman A, Setouhi A, et al. The Relationship of Fetuin-A with Coronary Calcification, Carotid Atherosclerosis, and Mortality Risk in Non-Dialysis Chronic Kidney Disease. Journal of lipid and atherosclerosis. 2024;13(2):194-211. https://doi.org/10.12997/jla.2024.13.2.194.

13. Rigal S, Casas B, Kanebratt KP, Wennberg Huldt C, Magnusson LU, Müllers E, et al. Normoglycemia and physiological cortisone level maintain glucose homeostasis in a pancreas-liver microphysiological system. Communications Biology. 2024;7(1):877.

https://doi.org/10.1038/s42003-024-06514-w.

14. Chekol Abebe E, Tilahun Muche Z, Behaile T/Mariam A, Mengie Ayele T, Mekonnen Agidew M, Teshome Azezew M, et al. The structure, biosynthesis, and biological roles of fetuin-A: A review. Frontiers in Cell and Developmental Biology. 2022; 10 - 2022:01-18.

https://doi.org/10.3389/fcell.2022.945287.

15. Icer MA, Yıldıran H. Effects of fetuin-A with diverse functions and multiple mechanisms on human health. Clinical Biochemistry. 2021;88:1-10. https://doi.org/10.1016/j.clinbiochem.2020.11.004.

16. Odiase P, Ma J, Ranganathan S, Ogunkua O, Turner WB, Marshall D, et al. The Role of Fetuin-A in Tumor Cell Growth, Prognosis, and Dissemination. International Journal of Molecular Sciences. 2024;25(23). https://doi.org/10.3390/ijms252312918.

17. Pagan LU, Gatto M, Martinez PF, Okoshi K, Okoshi MP. Biomarcadores em Doenças Cardiovasculares: O Papel da Fetuína-A. Arquivos Brasileiros de Cardiologia. 2022;118. https://doi.org/10.36660/abc.20210980.

18. Dogru T, Kirik A, Gurel H, Rizvi AA, Rizzo M, Sonmez A. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. International Journal of Molecular Sciences. 2021;22(12). https://doi.org/10.3390/ijms22126627.

19. Magalhães P, Zürbig P, Mischak H, Schleicher E. Urinary fetuin-A peptides as a new marker for impaired kidney function in patients with type 2 diabetes. Clinical Kidney Journal. 2021;14(1):269-76. https://doi.org/10.1093/ckj/sfaa176.

20. Wagner R, Machann J, Guthoff M, Nawroth PP, Nadalin S, Saleem MA, et al. The protective effect of human renal sinus fat on glomerular cells is reversed by the hepatokine fetuin-A. Scientific Reports. 2017;7(1):2261. https://doi.org/10.1038/s41598-017-02210-4.

21. Bourebaba L, Marycz K. Pathophysiological Implication of Fetuin-A Glycoprotein in the Development of Metabolic Disorders: A Concise Review. Journal of Clinical Medicine. 2019;8(12). https://doi.org/10.3390/jcm8122033 .

22. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: Relationship with coronary artery calcification. Kidney International. 2005;67(3):1070-7. https://doi.org/10.1111/j.1523-1755.2005.00172.x.

23. Poznyak AV, Sadykhov NK, Kartuesov AG, Borisov EE, Sukhorukov VN, Orekhov AN. Atherosclerosis Specific Features in Chronic Kidney Disease (CKD). Biomedicines. 2022;10(9). https://doi.org/10.3390/biomedicines10092094.

24. . Sun X, Liu Y. Matrix Metalloproteinase-10 in Kidney Injury Repair and Disease. Inte J Mol Sci. 2022;23(4):2131. https://doi.org/10.3390/ijms23042131.

25. Garcia-Fernandez N, Jacobs-Cachá C, Mora-Gutiérrez JM, Vergara A, Orbe J, Soler MJ. Matrix Metalloproteinases in Diabetic Kidney Disease. Journal of Clinical Medicine. 2020;9(2). https://doi.org/10.3390/jcm9020472.

26. Li B, Shaikh F, Younes H, Abuhalimeh B, Zamzam A, Abdin R, et al. Matrix Metalloproteinases 7 and 10 Are Prognostic Biomarkers for Systemic Cardiovascular Risk in Individuals with Peripheral Artery Disease. Biomolecules. 2025;15(6). https://doi.org/10.3390/biom15060853.

27. Molière S, Jaulin A, Tomasetto C-L, Dali-Youcef N. Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Metabolism: Insights into Health and Disease. International Journal of Molecular Sciences. 2023;24(13):10649. https://doi.org/10.3390/ijms241310649.

28. Mora-Gutiérrez JM, Rodríguez JA, Fernández-Seara MA, Orbe J, Escalada FJ, Soler MJ, et al. MMP-10 is Increased in Early Stage Diabetic Kidney Disease and can be Reduced by Renin-Angiotensin System Blockade. Scientific Reports. 2020;10(1):26. https://doi.org/10.1038/s41598-019-56856-3.

29. Ahmad J. Management of diabetic nephropathy: Recent progress and future perspective. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2015;9(4):343-58. https://doi.org/10.1016/j.dsx.2015.02.008.

30. Lv Y, Ye C, Li Z, Ye J, Cao H, Zhang C, et al. Tubular Injury in Diabetic Kidney Disease: Early Diagnosis and Intervention Strategies. Diabetes/Metabolism Research and Reviews. 2025;41(7):e70098. https://doi.org/10.1002/dmrr.70098.

31. Chen Y, Lee K, Ni Z, He John C. Diabetic Kidney Disease: Challenges, Advances, and Opportunities. Kidney Diseases. 2020;6(4):215-25.

https://doi.org/10.1159/000506634.

32. A. Mitkees N, M. El-Sayed H, M. Gad A, H. Mansour H, A. Mohamed N. FETUIN A AS AN EARLY MARKER OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Al-Azhar Medical Journal. 2020;49(2):785-96. https://doi.org/10.21608/amj.2020.82592.

33. Zuo Y, Wang C, Sun X, Hu C, Liu J, Hong X, et al. Identification of matrix metalloproteinase-10 as a key mediator of podocyte injury and proteinuria. Kidney International. 2021;100(4):837-49. https://doi.org/10.1016/j.kint.2021.05.035.

34. Öner-İyidoğan Y, Koçak H. Interaction of fetuin-A with obesity related insulin resistance and diabetes mellitus. Turkish Journal of Biochemistry. 2025;50(2):170-82. https://doi.org/10.1515/tjb-2024-0235.

35. Jahnen-Dechent W, Heiss A, Schäfer C, Ketteler M, Towler DA. Fetuin-A Regulation of Calcified Matrix Metabolism. Circulation Research. 2011;108(12):1494-509. https://doi.org/10.1161/CIRCRESAHA.110.234260.

36. Lafta BT, Aubaid SH, Falih ES. Serum Levels of FABP4 and Fetuin-A as Potential Biomarkers in Thyroid Diseases: A Comparative Study. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ). 2025;8(2(Special)):S1-7. https://doi.org/10.54133/ajms.v8i2(Special).1362.

37. Öner-İyidoğan Y, Koçak H. Interaction of fetuin-A with obesity related insulin resistance and diabetes mellitus. 2025;50(2):170-82. https://doi.org/10.1515/tjb-2024-0235.